Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Pharmaceutical industry continues to bet big on AI

Declining pharmaceutical research and development (R&D) efficiency has been an ongoing problem in pharmaceutical sector. With emerging technologies reshaping various business, pharma is looking to capitalize on artificial intelligence (AI) to streamline operating models and address R&D’s productivity challenges, says GlobalData, a leading data and analytics company. According to a survey as part of GlobalData’s latest report, Digital Transformation and […]
Read more

Akebia’s vadadustat MACE profile remains unclear and US approval path in non-dialysis CKD anemia uncertain

Akebia Therapeutics presented additional data from its Phase III PRO2TECT trial at the 2020 American Society of Nephrology Kidney Week conference, that evaluated the efficacy and safety of vadadustat versus erythropoiesis stimulating agent (ESA) Aranesp (darbepoetin alfa) for the treatment of chronic kidney disease (CKD) anemia in adult non-dialysis patients. Despite the latest additional data, […]
Read more

BrainStorm’s NurOwn fails Phase III trial, demonstrating the struggle to develop effective ALS treatment

Following Brainstorm Cell Therapeutics announcement of topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy NurOwn; Sarah Elsayed, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view on the opportunities and challenges in this market: “NurOwn is the second pipeline drug to fail a clinical trial for ALS this year, […]
Read more

US, UK and Germany are top manufacturers for COVID-19 vaccines

Vaccine developers are selecting contract manufacturing organizations (CMOs) close to home for their COVID-19 vaccine, as the US, UK and Germany are the most popular supplier locations, says GlobalData, a leading data and analytics company. Johanna Swanson, MBA, Product Manager at GlobalData, comments: “These supply chains contrast with the general trend within the pharma industry to […]
Read more

The Italian acromegaly market will more than double in size by 2029, says GlobalData

Marketed therapeutics for the treatment of acromegaly generated sales of at least $33m in Italy in 2019. The value of this market is expected to more than double, surpassing $75m in 2029, according to GlobalData, a leading data and analytics company. GlobalData’s recently published report, ‘Acromegaly and Gigantism: Global Drug Forecast and Market Analysis to 2029’, reveals that the size of the Italian acromegaly market will increase at a 10-year compound annual growth rate (CAGR) of 8.6%. Magdalene Crabbe, Senior Pharmaceutical Analyst at GlobalData, comments: “The Italian market will experience rapid […]
Read more

Kala Pharmaceuticals should focus on educating ophthalmologists and having a favorable price point for Eysuvis

The US Food and Drug Administration (FDA) recently announced the approval of Kala Pharmaceuticals’ Eysuvis, a topical steroid (0.25% loteprednol etabonate ophthalmic suspension), for short-term treatment of the signs and symptoms of dry eye syndrome (DES). In order to smoothen market access for this new therapy and facilitate its uptake, Kala Pharmaceuticals will need to […]
Read more

COVID-19 vaccine production driving contract service agreements for recombinant vector vaccines

COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19 vaccine developers are signing contract service agreements at an unprecedented rate, as pharma companies have publicly revealed 42 contract manufacturing service agreements for 28 unique pipeline COVID-19 vaccines, as manufacturing companies […]
Read more

Growth of T2D market driven by increasing diagnosed prevalence of disease and emergence of novel pipeline agents

Type 2 diabetes (T2D) is a crowded and competitive landscape, with market growth primarily driven by an increasing diagnosed prevalent population across nine major markets (9MM*) and the emergence of novel pipeline agents, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Type 2 Diabetes: Global Drug Forecast and Market Analysis to 2029’, reveals […]
Read more

Moderna and Pfizer raise the bar for COVID-19 vaccines and may ward off competing candidates in development

Following the news that Moderna has announced its COVID-19 vaccine, mRNA-1273, is 94.5% effective in first interim data readout; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology at GlobalData, a leading data and analytics company, offers his view: “While the efficacy of Moderna’s offering is slightly higher than that reported for Pfizer/BioNTech’s candidate, the […]
Read more

Diabetes market continues to evolve rapidly

Across the seven major markets* (7MM), the diagnosed prevalence of type 1 and 2 diabetes (T1D) was approximately 3.7 million and 49.7 million, respectively, in 2020 – according to data and analytics company GlobalData. This is expected to grow to more than 4.3 million by 2025 for Type 1 and 54.4 million for Type 2 […]
Read more

Avastin and Tecentriq combination to take over standard of care in hepatocellular carcinoma, says GlobalData

Following the string of approvals this year for Roche’s combination of Avastin (bevacizumab) and Tecentriq (atezolizumab), key opinion leaders interviewed by GlobalData from the five major European pharmaceutical markets (5EU*) and China have noted that the majority of patients would receive Avastin plus Tecentriq in the first-line setting. This offers a major competition to current […]
Read more

Key players in breast cancer space engage effectively with Japanese patients through unbranded digital strategies, says GlobalData

In Japan, the breast cancer treatment landscape consists of various systemic therapies including chemotherapy, hormonal therapy, targeted therapy and immunotherapy. Key players in this space provide competitive digital support through branded and unbranded channels. However, patient engagement through unbranded channels to create disease awareness has been more prominent, observes GlobalData, a leading data and analytics […]
Read more
1 … 76 77 78 79 80 … 110